TIXiMED Chief Scientific Officer Presents at 2023 Immunology of Diabetes Society Congress

Dr. Anath Shalev, renowned diabetes researcher and Chief Scientific Officer of TIXiMED, Inc., a company dedicated to the development and commercialization of TXNIP inhibiting medications, presented her work on verapamil and TXNIP inhibition at the 2023 Immunology of Diabetes Society Congress in Paris.

BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED, a company developing and commercializing TXNIP inhibiting medications as therapeutics for type 1 and type 2 diabetes, congratulates Chief Scientific Officer Dr. Anath Shalev on her presentation at the 2023 Immunology of Diabetes Society (IDS) Congress in Paris. Shalev, who serves as Director of the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB), was invited by the IDS to give a Symposium talk on Innovative Interventions and Preclinical Development and presented her work on verapamil and TXNIP inhibition for the treatment of type 1 diabetes.

Over the course of four days, the IDS Congress features presentations and talks from clinical, scientific, and pharmaceutical researchers from around the world regarding the causes of type 1 diabetes as well as cutting-edge treatments for the disease. Through symposia, oral and poster presentations, 450 renowned researchers discussed the newest advances in disease pathophysiology and treatment of type 1 diabetes. “We are thrilled that Dr. Shalev was invited to share her expertise about breakthrough treatments for type 1 diabetes at this esteemed Congress,” says Mike Goodrich, President and Executive Board Chair of TIXiMED. “TIXiMED is also proud to build on Shalev’s outstanding research on a novel small molecule TXNIP inhibitor to develop a treatment with the potential to offer new hope for diabetes patients.”

About Dr. Anath Shalev

Dr. Shalev is an international expert on the molecular biology of diabetes. Her research centers on beta cell biology, apoptosis, oxidative stress, transcriptional regulation of gene expression, and development of novel therapies for diabetes. Dr. Shalev’s laboratory identified thioredoxin-interacting protein, or TXNIP, as a therapeutic target that can be used to block the death of pancreatic beta cells and preserve a diabetes patient’s ability to produce insulin. Dr. Shalev holds the Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Juvenile Diabetes Research in the UAB Heersink School of Medicine. Currently, she serves as the Director of the UAB Comprehensive Diabetes Center and as a Professor in the UAB Department of Medicine’s Division of Endocrinology, Diabetes, and Metabolism.

About TIXiMED

TIXiMED is a company dedicated to developing and commercializing a TXNIP inhibiting molecule (TIX100) as a first-of-its kind oral therapeutic for type 1 and type 2 diabetes. TIXiMED is the exclusive license holder for the underlying patent surrounding the TIX100 molecule, a novel, small molecule TXNIP inhibitor that has been shown to protect against models of type 1 and type 2 diabetes as well as non-alcoholic fatty liver disease. Visit www.tiximed.com for more information.

About the First Avenue Ventures Life Science Fund I, LP

The mission of First Avenue Ventures is to help grow the Birmingham entrepreneurial ecosystem. To that end, First Avenue launched the First Avenue Ventures Life Science Fund I. The multi-million-dollar Fund aims to invest in early-stage drugs, therapies, and devices, with a particular focus on research developed at the University of Alabama at Birmingham. By providing financial and human capital, the Fund hopes to generate and scale local life science activity and to drive momentum in the broader entrepreneurial ecosystem. Visit www.favfunds.com for more information.

Emma Bolden
Director
First Avenue Ventures
205-578-1005